Bispecific CAR T-cells, engineered to simultaneously recognize HER2 and a second tumor-associated antigen, such as gp100 or MUC1, have shown the ability to eliminate solid tumors in preclinical models, including those located in the breast and brain of immunocompetent mice. This evidence concerns the gene MUC1 and neoplasm.